🔎 Trials Near Me

Home › Charcot-Marie-Tooth Disease › NCT01193075

Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others

RecruitingObservational studyHealthy volunteers welcome

Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Type (CMT1B), 2A (CMT2A), 4A (CMT4A), 4C (CMT4C), and Others

Who can join

All ages · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria

General Criteria

1\. All patients must agree to take part in the study and sign a consent form. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).

Patients:

1. Must have a documented, disease-causing variant(s) in a gene with a known or preliminary association with CMT gene as per Strande et al. 2017 AND consistent with the inheritance pattern associated with the genetic subtype (heterozygous in autosomal dominant, biallelic in autosomal recessive, hemizygous males with X-linked).
2. OR have a first- or second-degree family member (parent, child, sibling, half-sibling, aunt, uncle, grandparent, or grandchild) with a documented disease-causing variant(s) as above AND a clear link between that family member and the affected patient AND a phenotype consistent with the diagnosis.
3. In cases where clear links are not available, genetic confirmation is required.
4. Patients who have a variant(s) of uncertain significance on clinical laboratory reports may still be included if:
5. The variant is categorized as pathogenic or likely pathogenic per the "Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology." (Richards et al., 2015)
6. OR the variant has been found in multiple affected people in a family and has not been found in unaffected family members per "ClinGen guidance for use of the PP1/BS4 co-segregation and PP4 phenotype specificity criteria for sequence variant pathogenicity classification." (Biesecker et al. 2023)
7. OR the principal investigator and the site investigator agree that the variant(s) is (are) likely disease-causing.

Controls

1. Must not have a peripheral neuropathy, as determined by the site investigator.
2. Must have understood and signed an IRB approved consent form for the study. Teenagers (age 13-17 years) must sign an assent form (depending on local ethics committee requirements).

Exclusion Criteria

Patients:

1. Patient does not wish to participate or does not sign a consent form.
2. Patient has a different potential cause for their neuropathy AND no disease-causing variant(s).
3. Deemed inappropriate by the Site PI.

About the study

This is an observational longitudinal study to determine the natural history and genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease (CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).

The investigators will also be determine the capability of the newly developed CMT Pediatric Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform longitudinal measurements in patients with multiple forms of CMT over a five year window

Sponsor: Michael Shy · Participants: 5,000 · Started: Apr 1, 2010

Contact the study team

Official record on ClinicalTrials.gov — NCT01193075

Locations in the U.S.

CaliforniaCedars-Sinai Medical Center, Los Angeles
Stanford University, Palo Alto
ColoradoUniversity of Colorado Hospital, Aurora
ConnecticutUniversity of Connecticut/Connecticut Children's Medical Center, Hartford
FloridaUniversity of Miami, Miami
IowaUniversity of Iowa, Iowa City
MarylandJohns Hopkins University, Baltimore
MassachusettsHarvard/Massachusetts General Hospital, Boston
MichiganUniversity of Michigan, Ann Arbor
MinnesotaUniversity of Minnesota, Minneapolis
New YorkUniversity of Rochester, Rochester
North CarolinaUniversity of North Carolina, Chapel Hill
OhioNationwide Children's Hospital, Columbus
PennsylvaniaChildren's Hospital of Philadelphia, Philadelphia
University of Pennsylvania, Philadelphia
TennesseeSt. Jude Children's Research Hospital, Memphis
TexasHouston Methodist Hospital, Houston
WashingtonSeattle Children's Hospital, Seattle

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.